Evidence map›Paper›PMID 42487012›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

The relationship of EBER, EGFR, p16, and E-cadherin expressions with epithelial-mesenchymal transition and tumor budding in laryngeal squamous cell carcinoma.

Özgecan Gündoğar, Sibel Bektaş, Pelin Akbaş, Fatih Tetik

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Özgecan GündoğarDepartment of Pathology, Gaziosmanpasa Training and Research Hospital, University of Health Sciences, Istanbul, İstanbul, 34250, Türkiye. ozgecankarahan@hotmail.com.ORCID http://orcid.org/0000-0003-3075-6063
Sibel BektaşDepartment of Pathology, Gaziosmanpasa Training and Research Hospital, University of Health Sciences, Istanbul, İstanbul, 34250, Türkiye.ORCID http://orcid.org/0000-0003-0248-9869
Pelin AkbaşDepartment of Pathology, Gaziosmanpasa Training and Research Hospital, University of Health Sciences, Istanbul, İstanbul, 34250, Türkiye.ORCID http://orcid.org/0000-0002-5421-4317
Fatih TetikDepartment of Otorhinolaryngology, Gaziosmanpaşa Training and Research Hospital, University of Health Sciences, Istanbul, 34250, Türkiye.ORCID http://orcid.org/0000-0001-7468-6111

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLaryngeal squamous cell carcinoma (LSCC) is a tumor characterized by high biological heterogeneity. According to our literature review, this study is the first to analyze the expression profiles of EGFR, p16, E-cadherin, and EBER in combination with epithelial-mesenchymal transition (EMT) and tumor budding (TB), which represent the most critical dynamics of the invasive tumor front, and to demonstrate the quantitative hierarchy among these parameters. The aim of this study was to determine the independent predictive value of these biomarkers in identifying the aggressive phenotype. MATERIALS AND

methodsA total of 61 LSCC cases were included in this retrospective cohort study. Tumor budding (according to ITBCC 2016 criteria), EMT, perineural invasion (PNI), and tumor-infiltrating lymphocytes (TILs) were evaluated histopathologically. EGFR, p16, and E-cadherin expression were assessed by immunohistochemistry, while EBER status was evaluated using in situ hybridization (SISH). The data were modeled using binary logistic regression analysis.

resultsTumor budding was detected in 54.1% of the cases, while EMT was observed in 37.7%. According to multivariate analysis, EGFR positivity increased the risk of an aggressive phenotype by 50.058-fold (p=0.018), and p16 positivity increased the risk by 17.818-fold (p=0.004), identifying them as the strongest independent risk factors. Preservation of E-cadherin reduced the risk by 95% (OR: 0.049, p=0.016). No independent association was found between EBER expression or TIL presence and the aggressive phenotype (p>0.05).

conclusionThis study demonstrates that a molecular signature characterized by EGFR and p16 positivity together with loss of E-cadherin identifies the most aggressive subgroup of LSCC patients, characterized by high-grade tumor budding and EMT. As the first study integrating this four-marker molecular panel with invasive tumor front parameters, our findings provide a novel prognostic perspective in laryngeal carcinogenesis.

Indexed as

CadherinsCarcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16Epithelial-Mesenchymal TransitionLaryngeal NeoplasmsAdultAgedAntigens, CDBiomarkers, TumorErbB ReceptorsFemaleHumansImmunohistochemistryMaleMiddle AgedNeoplasm InvasivenessAntigens, CDBiomarkers, TumorCadherinsCDH1 protein, humanCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16EGFR protein, humanErbB ReceptorsE-cadherinEGFREMTLaryngeal cancerP16Tumor budding

Identifiers

PMID42487012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.